Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month results

Table 4 Renal function over 12 months (intent-to-treat population)

Visit window	Everolimus 1.5 mg (n= 61)				MMF 2 g (n= 61)
Visit window	n	Mean (SD)	Median (range)	P value ^avs. MMF	n	Mean (SD)	Median (range)
eGFR (MDRD) (ml/minute/1.73 m ² )
Baseline	61	12.17 (6.23)	10.70 (4.7 to 41.1)	0.420	61	14.00 (8.37)	11.00 (2.7 to 41.1)
Month 1	56	63.10 (25.441)	58.40 (18.5 to 123.3)	0.685	60	60.53 (19.339)	57.25 (23.5 to 14.7)
Month 12	56	62.09 (18.993)	58.00 (17.8 to 123.3)	0.063	58	56.34 (15.227)	55.25 (26.1 to 111.8)
	<30	≥30 to <60	≥60	P value vs. MMF	<30	≥30 to <60	≥60
Incidence rates of patients within renal function (eGFR MDRD) categories ( n /month, %)
Month 1	5/56 (8.9)	26/56 (46.4)	25/56 (44.6)	0.541	1/60 (1.7)	31/60 (51.7)	28/60 (46.7)
Month 12	1/56 (1.8)	29/56 (51.8)	26/56 (46.4)	0.152	1/58 (1.7)	38/58 (65.5)	19/58 (32.8)

^aWilcoxon rank-sum test comparing everolimus and MMF values. eGFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease; MMF, mycophenolate mofetil; SD, standard deviation.

ISSN: 2047-1440